Pharmacists warn drug shortage affecting cancer patients
- Pharmacists warn that as of 2025, more than 61,000 UK patients needing Creon face a critical shortage affecting cancer and other conditions.
- The shortage results from Europe-wide raw ingredient scarcity and manufacturing capacity limits causing extended supply disruptions since at least 2023.
- Patients, like 64-year-old Alice with pancreatic cancer, now receive reduced Creon supplies forcing them to skip meals, risking their health and chemotherapy tolerance.
- Surveys show 96% of pharmacies have trouble supplying Creon and 81% say shortage management is inadequate, with some patients traveling over 30 miles to find the drug.
- Authorities extended shortage protocols until November 2025 while experts call for urgent government action and options like importing to resolve this ongoing health crisis.
11 Articles
11 Articles
Cancer patients 'skipping meals' amid 'one of worst' medicine shortages to affect UK
More than 61,000 UK patients with pancreatic cancer, cystic fibrosis, and chronic pancreatitis are facing severe shortages of Creon, a vital digestive medicine. Pharmacists have warned that this represents "one of the worst" examples of medicine shortages currently affecting the country.The pancreatic enzyme replacement therapy helps patients digest food and is essential for their survival. Without it, patients lose weight and strength, reducing…
WAPCP Conference: Pharmacists Seek Better Medicine Security Through Compounding
The West African Postgraduate College of Pharmacists (WAPCP), Abuja Zone, has stressed the importance of drug compounding, mini-production, and quality control services in health facilities to improve medicines’ availability and quality. The pharmacists stated this during their 6th Annual Scientific Conference over the weekend. In his welcome address, WAPCP Zonal Coordinator Dr Abubakar Danraka emphasised that these services can improve patient …
Coverage Details
Bias Distribution
- 43% of the sources lean Left, 43% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage